Hims & Hers Health is trading at €29.56 (-5.50%) as the stock continues to face pressure from regulatory uncertainty and shifting sentiment regarding its weight-loss segment.
- Investor caution remains high due to concerns over the sustainability of compounded GLP-1 sales and a recent warning letter from the FDA.
- The market is weighing the potential impact of the semaglutide shortage ending, which could increase competitive pressure from brand-name pharmaceutical manufacturers.
- Today's decline appears to be a continuation of recent analyst weakness rather than a response to a specific new catalyst.